Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2017 2
2018 2
2019 4
2021 3
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

12 results
Results by year
Filters applied: . Clear all
Page 1
Tumor-Associated Macrophages in Vestibular Schwannoma and Relationship to Hearing.
Nisenbaum E, Misztal C, Szczupak M, Thielhelm T, Peña S, Mei C, Goncalves S, Bracho O, Ma R, Ivan ME, Morcos J, Telischi F, Liu XZ, Fernandez-Valle C, Dinh CT. Nisenbaum E, et al. Among authors: bracho o. OTO Open. 2021 Nov 23;5(4):2473974X211059111. doi: 10.1177/2473974X211059111. eCollection 2021 Oct-Dec. OTO Open. 2021. PMID: 34870062 Free PMC article.
A Xenograft Model of Vestibular Schwannoma and Hearing Loss.
Dinh CT, Bracho O, Mei C, Bas E, Fernandez-Valle C, Telischi F, Liu XZ. Dinh CT, et al. Among authors: bracho o. Otol Neurotol. 2018 Jun;39(5):e362-e369. doi: 10.1097/MAO.0000000000001766. Otol Neurotol. 2018. PMID: 29557843 Free PMC article.
Fluorescent Detection of Merlin-deficient Schwann Cells and Primary Human Vestibular Schwannoma Cells Using Sodium Fluorescein.
Perez ER, Bracho O, Ein L, Szczupak M, Monje PV, Fernandez-Valle C, Alshaiji A, Ivan M, Morcos J, Liu XZ, Hoffer M, Eshraghi A, Angeli S, Telischi F, Dinh CT. Perez ER, et al. Among authors: bracho o. Otol Neurotol. 2018 Sep;39(8):1053-1059. doi: 10.1097/MAO.0000000000001895. Otol Neurotol. 2018. PMID: 30001282 Free PMC article.
Ponatinib promotes a G1 cell-cycle arrest of merlin/NF2-deficient human schwann cells.
Petrilli AM, Garcia J, Bott M, Klingeman Plati S, Dinh CT, Bracho OR, Yan D, Zou B, Mittal R, Telischi FF, Liu XZ, Chang LS, Welling DB, Copik AJ, Fernández-Valle C. Petrilli AM, et al. Among authors: bracho or. Oncotarget. 2017 May 9;8(19):31666-31681. doi: 10.18632/oncotarget.15912. Oncotarget. 2017. PMID: 28427224 Free PMC article.
Preclinical assessment of MEK1/2 inhibitors for neurofibromatosis type 2-associated schwannomas reveals differences in efficacy and drug resistance development.
Fuse MA, Dinh CT, Vitte J, Kirkpatrick J, Mindos T, Plati SK, Young JI, Huang J, Carlstedt A, Franco MC, Brnjos K, Nagamoto J, Petrilli AM, Copik AJ, Soulakova JN, Bracho O, Yan D, Mittal R, Shen R, Telischi FF, Morrison H, Giovannini M, Liu XZ, Chang LS, Fernandez-Valle C. Fuse MA, et al. Among authors: bracho o. Neuro Oncol. 2019 Mar 18;21(4):486-497. doi: 10.1093/neuonc/noz002. Neuro Oncol. 2019. PMID: 30615146 Free PMC article.
12 results